Join us in Athens Georgia for Innovation Gateway's Startup Stories. This month will feature Richard Shimkets, Ph.D., President and CEO of Abeome Corporation.
An exclusive panel of pioneering Athens startup company founders will candidly discuss their innovations and journey from academic research to commercial success.

Join us in Athens Georgia for Innovation Gateway's Startup Stories. This month will feature Richard Shimkets, Ph.D., President and CEO of Abeome Corporation.

Abeome is a privately held antibody discovery company focused on the high-throughput selection, analysis and synthesis of monoclonal antibodies. The company’s primary objective is to develop best-in-class prescription products for the therapeutic antibody market, the fastest growing segment of global drug sales. Abeome’s DiSH™ technology enables the rapid detection and production of highly specific monoclonal antibodies. Using DiSH, desired monoclonals can be identified using fluorescent-labeled antigens to bind surface-expressed antibodies, making isolation and cloning of desired cells significantly easier. Abeome’s AbeoMouse™ platform enables the direct selection of desirable functional antibodies straight from the immune system of an immunized mouse. Traditional technology requires the screening of thousands of antibodies to find a handful with drug-like properties. The direct probing of the AbeoMouse™ can reveal high affinity antibodies that block the function of the target.